<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099835</url>
  </required_header>
  <id_info>
    <org_study_id>000092</org_study_id>
    <nct_id>NCT05099835</nct_id>
  </id_info>
  <brief_title>Ultrasound-Guided Stellate Ganglion Block With Botulinum</brief_title>
  <official_title>Ultrasound-Guided Stellate Ganglion Block With Botulinum Toxin Versus Steroid in Refractory Bell's Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the local stellate ganglion block with bupivacaine and corticosteroid treatment for acute&#xD;
      peripheral facial nerve palsy in patients can induce hyperglycemia, and an alternative local&#xD;
      therapy may be necessary and some time may ve ineffective. Our purpose in this study is to&#xD;
      evaluate therapeutic effects of stellate ganglion block (SGB) Botulinum Toxin on referactory&#xD;
      facial nerve palsy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      :Idiopathic facial nerve palsy (Bell's palsy) is caused by damage to the facial nerve at any&#xD;
      site of the peripheral branches after the facial nucleus.Stellate ganglion block is inteneded&#xD;
      to increase blood flow and promotes nerve regeneration. the local stellate ganglion block&#xD;
      with bupivacaine and corticosteroid treatment for acute peripheral facial nerve palsy in&#xD;
      patients can induce hyperglycemia, and an alternative local therapy may be necessary and some&#xD;
      time may ve ineffective. Our purpose in this study is to evaluate therapeutic effects of&#xD;
      stellate ganglion block (SGB) Botulinum Toxin on referactory facial nerve palsy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline House-Brackmann</measure>
    <time_frame>: Baseline ,change from baseline House-Brackmann at 7th day,one month,two month, three month</time_frame>
    <description>Change from Baseline House-Brackmann</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Change From Baseline House-Brackmann</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injected 10 mL of 0.25% bupivacaine with triamcinolonacetonide 4 mg/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox</intervention_name>
    <description>injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)</description>
    <arm_group_label>Botulinum Toxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolonacetonide</intervention_name>
    <description>triamcinolonacetonide stellate ganglion injection</description>
    <arm_group_label>steroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed by clinical and neurological assessment as one-sided idiopathic facial palsy&#xD;
&#xD;
          -  Age 18 to 60 •-ASA i-II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
               -  diabetic&#xD;
&#xD;
               -  coagulation dysfunction&#xD;
&#xD;
               -  mental or cognitive dysfunclion&#xD;
&#xD;
               -  allergy to injected medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emad Zarief Kamel Said</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Emad Zarief , MD</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganglion Cysts</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

